Effects of treatment with exenatide on bone
Phase 1
Active, not recruiting
- Conditions
- bone metabolismMedDRA version: 18.0Level: HLTClassification code 10067225Term: Biochemical markers of bone metabolismSystem Organ Class: 100000004848Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Registration Number
- EUCTR2014-002124-27-DK
- Lead Sponsor
- Endocrine Research Unit, Odense University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
healthy postmenopausal women
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 66
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 66
Exclusion Criteria
-primary hyperparathyroidism
- treatment with metformin or any other drug used for the treatment of type 2 diabetes, antiresorptive drugs, glucocorticoids, aromatase inhibitors, HRT, anti-epileptic drugs
- diseases associated with osteoporosis including RA, renal insufficiency, thyreotoxicosis, type 1 diabetes, severe COPD
- pancreatitis
- fractures < 6 months
- allergy towards exenatide
- excessive intake of alcohol
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method